KRAS and non-small cell lung carcinoma: Tetrac and NDAT also effectively inactivate the phosphorylation of the VEGFR and ERK1/2 signaling pathway and improve heteronemin-induced antiproliferative activity in KRAS mutant NSCLC cells [12].